[1] Altekruse SF, Mcglynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 2009, 27(9): 1485-1491.
[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391(10127): 1301-1314.
[3] GLOBOCAN 2020.http://gcoiarcfr/today
[4] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 临床肝胆病杂志, 2020, 36(2): 277-292.
[5] 中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版). 实用肝脏病杂志 2021, 24(2):S3-S13.
[6] Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. JHepatol, 2021, 75(6): 1476-1484.
[7] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1): 73-84.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 实用肝脏病杂志 2018, 21:177-186.
[9] Kanwal F, Kramer JR, Mapakshi S, et al. Risk ofhepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology, 2018, 155(6): 1828-1837 e1822.
[10] Ioannou GN, Green P, Lowy E, et al. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS One, 2018, 13(9): e0204412.
[11] Ioannou GN, Green P, Kerr KF, et al. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol, 2019, 71(3): 523-533.
[12] White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.Clin Gastroenterol Hepatol, 2012, 10(12): 1342-1359.e1342.
[13] Sorensen HT, Mellemkjaer L, Jepsen P, et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol, 2003, 36(4): 356-359.
[14] Kawamura Y, Arase Y, IkedaK, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol, 2012, 107(2): 253-261.
[15] Adams LA, Lymp JF, St Sauver J, et al. The natural history ofnonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129(1): 113-121.
[16] Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholicsteatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol, 2019, 17(4): 748-755.e743.
[17] Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology, 2017, 65(3): 804-812.
[18] 范建高,曾静. 非酒精性脂肪性肝病的流行现状与危害.中华消化杂志,2020,40(9):577-580.
[19] Zhou J, Zhou F, Wang W, et al. Epidemiologicalfeatures of NAFLD from 1999 to 2018 in China. Hepatology, 2020, 71(5): 1851-1864.
[20] Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018, 67(1): 123-133.
[21] Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol, 2018, 69(4): 896-904.
[22] Gawrieh S, Dakhoul L, Miller E, et al. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther, 2019, 50(7): 809-821.
[23] Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2012, 11(1): 18-27.
[24] Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary PancreatDis Int, 2005, 4(2): 173-177.
[25] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1): 202-209.
[26] Eslam M, Sarin SK, Wong VW, et al.The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int, 2020, 14(6): 889-919.
[27] Ren TY, Fan JG. What are the clinical settings and outcomes of lean NAFLD? Nat Rev Gastroenterol Hepatol, 2021, 18(5): 289-290.
[28] Kramer JR, Natarajan Y, Dai J, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Hepatology, 2021[ahead of print].
[29] Memel ZN, Arvind A, Moninuola O, et al. Aspirinuse is associated with a reduced incidence of hepatocellular carcinoma: A systematic review and Meta-analysis. Hepatol Commun, 2021, 5(1): 133-143.
[30] Singh S, Singh PP, Singh AG, et al.Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology, 2013, 144(2): 323-332.
[31] Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol, 2013, 108(6): 881-891; quiz 892.
[32] Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021, 184(10): 2537-2564.
[33] Liang JQ, Teoh N, Xu L, et al. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nat Commun, 2018, 9(1): 4490.
[34] Duan XY, Zhang L, Fan JG, et al. NAFLD leads to liver cancer: do we have sufficientevidence? Cancer Lett, 2014, 345(2): 230-234.
[35] Bianco C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol, 2021, 74(4): 775-782.
[36] Gellert-Kristensen H, Richardson TG, Davey Smith G, et al. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology, 2020, 72(3): 845-856.
[37] Fan JG, Farrell GC. Prevention of hepatocellularcarcinoma in nonviral-related liver diseases. J Gastroenterol Hepatol, 2009, 24(5): 712-719.
[38] Chernyak V, Fowler KJ, Kamaya A, et al. Liverimaging reporting and aata system (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology, 2018, 289(3): 816-830.
[39] Kim HL, An J, Park JA, et al. Magneticresonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology, 2019, 69(4): 1599-1613.
[40] Chang XJ, Shi YW, Wang J, et al.Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary Pancreat Dis Int, 2021, 20(5): 416-425.
[41] 中国肝炎防治基金会肝细胞癌筛查和监测项目专家组. 慢性乙型肝炎病毒感染者肝细胞癌筛查和监测. 实用肝脏病杂志 2021, 24(6):776-787.
[42] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis,staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68(2): 723-750.
[43] EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018, 69(1): 182-236.
[44] Loomba R, Lim JK, Patton H, et al. AGAclinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: Expert review. Gastroenterology, 2020, 158(6): 1822-1830.
[45] 李晓燕,胡和平. 加强肝癌内科队伍建设,重视肝癌内科规范化和个性化诊疗决策. 实用肝脏病杂志, 2021, 24(1):1-3. |
